Navigation Links
AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
Date:3/12/2008

WILMINGTON, Del., March 12 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that it has completed patient enrollment in two pivotal Phase III studies for vandetanib, the company's investigational, once-daily oral anti-cancer drug, for the second-line treatment of non-small cell lung cancer (NSCLC). The two studies -- ZODIAC (ZACTIMA in cOmbination with Docetaxel In non-smAll cell lung Cancer) and ZEAL (ZACTIMA Efficacy with Alimta in Lung cancer) -- are the second and third of four ongoing studies to complete enrollment. Data from the studies are expected later this year and the broad development program is on track for a first regulatory submission in 2008.

ZODIAC is a randomized, double-blind, international, multi-center Phase III study to assess the efficacy of vandetanib 100mg once-daily plus the standard docetaxel chemotherapy versus docetaxel alone in 1,380 patients with locally advanced or metastatic NSCLC after failure of first-line anti-cancer therapy.

ZEAL is a Phase III parallel group, randomized, double-blind study evaluating vandetanib 100mg once daily plus pemetrexed 500mg/m2 (every 3 weeks) compared with placebo plus pemetrexed as second-line treatment in 510 patients with locally advanced or metastatic NSCLC who have failed first-line anti-cancer therapy.

The ZEST study, which is investigating vandetanib versus erlotinib, was the first Phase III study of vandetanib to complete enrollment in November 2007.

"NSCLC is an area of high unmet medical need, and we hope vandetanib will offer a beneficial new treatment option that may improve the lives of people with lung cancer," said Dr. Peter Langmuir, Medical Science Director at AstraZeneca.

ZODIAC and ZEAL are part of a broad Phase III clinical trial program designed to gain an understanding of how vandetanib may benefit people with lung cancer.
The other studies are:

-- ZEST (vandetanib versus erlotinib) enrollment is complete;
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
2. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
3. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
4. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
5. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
6. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
7. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
8. BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing
9. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
10. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
11. Plurality Completes R&D of its HAL-256 Multicore Processor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... NEWARK, Del., Feb. 19 Lightwave Logic, Inc. (OTC ... technology company focused on the development of electro-optic polymer ... optical computing, announced today the addition of Anthony J. ... for 30 years in medicinal chemistry and brings a ...
... - finally accepts legitimate call by shareholders to general ... - will not allow shareholder ... - persists with high risk, high funding, Avexa merger proposal. ... Meeting scheduled for 27 March 2009 MELBOURNE, Australia, Feb. 19 ...
... solar cell materials that are as abundant but much ... today could substantially reduce the cost of solar photovoltaics, ... Resources Group and the Department of Chemistry at the ... Laboratory (LBNL). , These materials, some of which ...
Cached Biology Technology:Lightwave Logic, Inc. Announces the Addition of Anthony J. Cocuzza, PhD to its Technology Team 2Progen Concedes Shareholder Requisitioned Meeting 2Progen Concedes Shareholder Requisitioned Meeting 3Progen Concedes Shareholder Requisitioned Meeting 4Progen Concedes Shareholder Requisitioned Meeting 5Cheaper materials could be key to low-cost solar cells 2Cheaper materials could be key to low-cost solar cells 3
(Date:7/9/2014)... injuries have identified an immune marker that predicts ... infection. The study, led by clinician-scientists at Nationwide ... the journal Shock , is part of ... clinical implementation of quick-turnaround immune function tests and ... following critical illness or injury in pediatric patients. ...
(Date:7/9/2014)... co-authored by a University of Guelph scientist that ... shows long-term exposure to a neonicotinoid pesticide hampers ... research by Nigel Raine, a professor in Guelph,s ... Imperial College London was published July 9 in ... . , The study shows how long-term pesticide ...
(Date:7/9/2014)... With over 100 diseases that can attack soybean crops, ... the most wanted list? University of Illinois scientists cite ... research is needed on the fungus that causes charcoal ... damp growing conditions but Macrophomina phaseolina , the ... drought conditions. , "As the climate continues to change ...
Breaking Biology News(10 mins):Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3Bee foraging chronically impaired by pesticide exposure: Study 2Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
... Athens, Ga. University of Georgia researchers are working ... white sturgeon, is struggling in northern California,s Sacramento-San Joaquin ... fish populations and pollution. Doug Peterson and Robert ... and Natural Resources, have begun work on the one-year, ...
... lakes has a seriously detrimental impact on people and ... to a study published in the current issue of ... the physicochemical properties and toxicology of water from and ... Singare of Bhavan,s College, in Mumbai, and colleagues highlight ...
... of the ocean floor to deep within the human gut ... such an overwhelming majority of life on earth that no ... they maintain the living world around us. Microbes may be ... the most important. In a new two volume ...
Cached Biology News:UGA researchers study threats to white sturgeon 2UGA researchers study threats to white sturgeon 3Heavy metal -- in and around the lakes 2Handbook of Molecular Microbial Ecology: Exploring the World of the Microbes 2
...
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
... Freedom EVO384R are fast multi-channel pipetting platforms ... different sizes, with a multi-channel head and ... time saving, with true parallel processing of ... your assays with the Freedom EVOware program. ...
... EVO96R and Freedom EVO384R are fast multi-channel ... in three different sizes, with a multi-channel ... deliver significant time saving, with true parallel ... setup of your assays with the Freedom ...
Biology Products: